CELLECTAR BIOSCIENCES, INC.
100 Campus Drive
Florham Park, New Jersey 07932
November 30, 2022
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jason Drory
| Re: | Cellectar Biosciences, Inc. | |
Registration Statement on Form S-1 Filed November 23, 2022 | ||
| File No. 333-268554 |
Ladies and Gentlemen:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Cellectar Biosciences, Inc., a Delaware corporation (the “Company”), hereby requests that the effective date of the Company’s Registration Statement on Form S-1 (Registration No. 333-268554), be accelerated so that the Registration Statement will become effective at 5:00 p.m. on December 2, 2022, or as soon as practicable thereafter.
The cooperation of the staff in meeting our request is very much appreciated. If you have any questions or comments, please contact Asher M. Rubin (410-559-2881 or arubin@sidley.com) or Istvan A. Hajdu (212-839-5651 or ihajdu@sidley.com). Thank you for your assistance with these matters.
| Very truly yours, | |||
| CELLECTAR BIOSCIENCES, INC. | |||
| By: | /s/ Chad J. Kolean | ||
| Chad J. Kolean, Chief Financial Officer | |||
| cc: | James V. Caruso Asher M. Rubin Istvan A. Hajdu |
